These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 22841588)

  • 21. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis.
    Moltó A; Ea HK; Richette P; Bardin T; Lioté F
    Joint Bone Spine; 2012 Dec; 79(6):621-3. PubMed ID: 22658375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
    Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
    J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic tophaceous gout.
    Dönmez S; Pamuk ÖN
    J Rheumatol; 2014 Mar; 41(3):554-5. PubMed ID: 24585523
    [No Abstract]   [Full Text] [Related]  

  • 24. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis.
    Kalliolias GD; Liossis SN
    Expert Opin Investig Drugs; 2008 Mar; 17(3):349-59. PubMed ID: 18321234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First observation of the efficacy of IL-1ra to treat tophaceous gout of the lumbar spine.
    Funck-Brentano T; Salliot C; Leboime A; Zafrani L; Servais A; Larousserie F; Dougados M
    Rheumatology (Oxford); 2011 Mar; 50(3):622-4. PubMed ID: 21097448
    [No Abstract]   [Full Text] [Related]  

  • 26. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure.
    Announ N; Palmer G; Guerne PA; Gabay C
    Joint Bone Spine; 2009 Jul; 76(4):424-6. PubMed ID: 19289295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subacute liver failure following anakinra treatment for adult-onset Still disease.
    Aly L; Iking-Konert C; Quaas A; Benten D
    J Rheumatol; 2013 Oct; 40(10):1775-7. PubMed ID: 24085761
    [No Abstract]   [Full Text] [Related]  

  • 28. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
    Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
    Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra).
    Vassilopoulos D; Lazaros G; Tsioufis C; Vasileiou P; Stefanadis C; Pectasides D
    Int J Cardiol; 2012 Sep; 160(1):66-8. PubMed ID: 22704870
    [No Abstract]   [Full Text] [Related]  

  • 30. Anakinra shows promise for treating patients with rheumatoid arthritis.
    McIntosh T; Freeman TR
    J Am Pharm Assoc (Wash); 2002; 42(4):660-2. PubMed ID: 12150367
    [No Abstract]   [Full Text] [Related]  

  • 31. Anakinra: an effective treatment in the Schnitzler syndrome.
    Vandenhende MA; Bentaberry F; Morlat P; Bonnet F
    Joint Bone Spine; 2011 Dec; 78(6):636-7. PubMed ID: 21550281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two cases of anakinra-induced neutropenia during auto-inflammatory diseases: drug reintroduction can be successful.
    Perrin F; Néel A; Graveleau J; Ruellan AL; Masseau A; Hamidou M
    Presse Med; 2014 Mar; 43(3):319-21. PubMed ID: 24456697
    [No Abstract]   [Full Text] [Related]  

  • 33. Long-term efficacy and safety of anakinra in a patient with Behçet's disease and concomitant tuberculosis infection.
    Emmi G; Silvestri E; Squatrito D; Vitale A; Bacherini D; Vannozzi L; Emmi L; D'Elios MM; Cantarini L; Prisco D
    Int J Dermatol; 2017 Feb; 56(2):218-220. PubMed ID: 27336860
    [No Abstract]   [Full Text] [Related]  

  • 34. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra.
    McGonagle D; Tan AL; Shankaranarayana S; Madden J; Emery P; McDermott MF
    Ann Rheum Dis; 2007 Dec; 66(12):1683-4. PubMed ID: 17998217
    [No Abstract]   [Full Text] [Related]  

  • 35. Role of interleukin-1 inhibitors in the management of gout.
    Tran TH; Pham JT; Shafeeq H; Manigault KR; Arya V
    Pharmacotherapy; 2013 Jul; 33(7):744-53. PubMed ID: 23553601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study.
    Nordström D; Knight A; Luukkainen R; van Vollenhoven R; Rantalaiho V; Kajalainen A; Brun JG; Proven A; Ljung L; Kautiainen H; Pettersson T
    J Rheumatol; 2012 Oct; 39(10):2008-11. PubMed ID: 22859346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection.
    Villegas C; Poza M; Talayero P; Teller JMC; Zafra D; Garcia C; Vera E; Hidalgo M; Lopez N; Cuellar C; Zamanillo I; Íñiguez R; Paz-Artal E; Aguado JM; Martinez-Lopez J
    Ann Hematol; 2020 Dec; 99(12):2953-2956. PubMed ID: 32583087
    [No Abstract]   [Full Text] [Related]  

  • 38. Effectiveness and Safety of Anakinra for Management of Refractory Pericarditis.
    Jain S; Thongprayoon C; Espinosa RE; Hayes SN; Klarich KW; Cooper LT; Moder KG; Anavekar NS; Oh JK; Matteson EL
    Am J Cardiol; 2015 Oct; 116(8):1277-9. PubMed ID: 26279106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis.
    Swart JF; Barug D; Möhlmann M; Wulffraat NM
    Expert Opin Biol Ther; 2010 Dec; 10(12):1743-52. PubMed ID: 20979564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anakinra for the treatment of rheumatoid arthritis: a safety evaluation.
    Ramírez J; Cañete JD
    Expert Opin Drug Saf; 2018 Jul; 17(7):727-732. PubMed ID: 29883212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.